There are many circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) following relapse or disease progression during therapy, and in a few cases, when a therapy is continued beyond disease progression. The authors comprehensively describe the available data on rechallenge and continuation beyond progression treatment strategies, discuss the potential mechanisms explaining tumour re-sensitization with reintroduced or continued therapy, and make the case for why drug resistance definitions need to be re-evaluated.
- Elizabeth A. Kuczynski
- Daniel J. Sargent
- Robert S. Kerbel